Stock analysts at Bank of America initiated coverage on shares of NextCure (NASDAQ:NXTC) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Bank of America‘s price target suggests a potential upside of 46.97% from the company’s previous close.

NXTC has been the subject of a number of other reports. Morgan Stanley lowered shares of Meili from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $14.00 to $4.20 in a research report on Monday, June 3rd. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a research report on Monday, June 3rd.

Shares of NXTC traded up $0.36 during mid-day trading on Tuesday, reaching $17.01. The stock had a trading volume of 43,365 shares, compared to its average volume of 85,281. NextCure has a 12 month low of $13.86 and a 12 month high of $22.75. The business’s fifty day moving average price is $16.68.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Monday, June 10th. The company reported ($4.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($3.93). The business had revenue of $1.36 million for the quarter. Equities research analysts expect that NextCure will post -1.34 EPS for the current year.

In related news, major shareholder X L.P. Canaan bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $15.00 per share, for a total transaction of $750,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stella Xu bought 125,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $15.00 per share, with a total value of $1,875,000.00. The disclosure for this purchase can be found here.

NextCure Company Profile

There is no company description available for NextCure Inc

Featured Story: Why is the price target of stocks important?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.